

Announcements

SECOND ROME INTERNATIONAL SYMPOSIUM ON BIOLOGICAL BASES AND CLINICAL IMPLICATIONS OF TUMOR RADIORESISTANCE

The Symposium, organized by an international Scientific Committee, will be held in Rome, Italy, on September 21-24, 1980, under the sponsorship of the Committee for Radiation Oncology Studies (C.R.O.S.)/National Cancer Institute, of the European Organization for Research on Treatment of Cancer (E.O.R.T.C.), and of the Società Italiana di Cancerologia (S.I.C.). The aim of the Symposium is to review the current status of radiotherapy, to develop a critical evaluation of the 'growing points' in the field, and to see what biologists and radiotherapists think should happen in the future in the treatment of cancer. The topics will include:

- Biological Factors Influencing Radioresistance
- Approaches to Exploiting Biological Phenomena
- Current Status and Growing Points of Radiotherapy
 - Unconventional Dose Delivery
 - Hypoxic Cell Sensitizers
 - Hyperthermia
 - Combined Drugs and Radiation
 - High Let Radiation

The program includes invited keynote addresses and lectures, poster session and a commercial exhibition.

For further information write to: 2nd Rome Symposium, Istituto Medico e di Ricerca Scientifica, Via Luigi Bodio 58, 00191 Rome, Italy.

E.O.R.T.C. UROLOGICAL GROUP—CURRENT CLINICAL TRIALS (JANUARY 1980)

Multicentre cooperative trials are currently in progress for patients with kidney, bladder, prostate and testicular cancer. An outline of the various studies is given below for the benefit of any investigator who might wish to participate. Detailed information can be obtained from the coordinators of each study who can be contacted through the Secretary of the Urological Group (Mr. Philip Smith, St. James's University Hospital, Leeds LS9 7TF, Tel. Leeds 33144) or the Chairman (Professor Michele Pavone-Macaluso, 9 via Villa Trabia, 90141 Palermo, Italy).

A. *Studies on Kidney Cancer*

Advanced carcinoma of the kidney with indicator lesions: a phase II study testing the effect of methyl-GAG.

B. *Studies on Bladder Cancer*

1. *Superficial bladder cancer:* effect of intravesical agents on recurrence rate. Two studies are currently active:
 - (a) Epodyl vs adriamycin vs control,
 - (b) Thiotepa vs adriamycin vs cis-platinum.
2. *Infiltrating but operable (T3, MO) bladder cancer:* effect of adjuvant chemotherapy with adriamycin and 5-fluorouracil on survival and recurrence rate after cystectomy with or without preoperative radiotherapy.
3. *Advanced bladder cancer with measurable lesions:* two phase II studies are available:
 - (a) Combination therapy with cis-platinum, adriamycin and cyclophosphamide (CAP),
 - (b) Vincristine for those not suitable for the CAP study.

C. Studies on Prostatic Cancer

1. *A comparative trial of hormonal agents:* two studies are active:
 - (a) Stilboestrol vs estramustine phosphate,
 - (b) Stilboestrol vs cyproterone vs medroxyprogesterone acetate.
2. *A phase II study for stage D patients with measurable lesions:* using vindesine.

D. Studies on Testicular Cancer—Non-seminoma

Several trials, which each require participation from a number of centers, are available:

1. *For advanced testicular cancer:*
 - (a) A comparison between two remission induction regimes, both containing cis-platinum,
 - (b) A comparison of maintenance vs no maintenance chemotherapy after successful remission induction.
2. *For patients with limited lymph node metastases:*

A comparison between chemotherapy and radiotherapy.
3. *For patients with advanced lymph node metastases:*

A comparison between chemotherapy and radiotherapy vs chemotherapy alone.
4. *For patients without macroscopic residual lymph node metastases after retroperitoneal lymph node dissection:*

A comparison between adjuvant chemotherapy vs salvage chemotherapy.

Enquiries are invited from anyone interested in cooperating in any of these studies.